Infographic: The Future of Prostate Cancer Biomarkers Is Multiplexed
Combining urinary biomarkers improves clinical utility and provides a more robust evaluation
Published:Jul 07, 2021
|1 min read
Combining urinary biomarkers allows a complete evaluation of prostate cancer cells while minimizing the risk of missing a foci of cancer or a unique mutation that drives clinical outcomes.
Here, we explore commercially available multiplex urine biomarkers for detecting prostate cancer.
